Lung cancer and elective nodal irradiation: A solved issue?

[Lung cancer and elective nodal irradiation: A solved issue?] Cancer Radiother. 2019 Sep 06;: Authors: Laurans M, Botticella A, Moukasse Y, Lévy A, Le Péchoux C Abstract Lung cancer treatment is a heavy workload for radiation oncologist and that field showed many evolutions over the last two decades. The issue about target volume was raised when treatment delivery became more precise with the development of three-dimensional conformal radiotherapy. Initially based upon surgical series, numerous retrospective and prospective studies aimed to evaluate the risk of elective nodal failure of involved-field radiotherapy compared to standard large field elective nodal irradiation. In every setting, locally advanced non-small cell lung cancer, localized non-small cell lung cancer, localized small cell lung cancer, exclusive chemoradiation or postoperative radiotherapy, most of the studies showed no significant difference between involved-field radiotherapy or elective nodal irradiation with elective nodal failure rate under 5% at 2 years, provided staging had been done with modern imaging and diagnostic techniques (positron emission tomography scan, endoscopy, etc.). Moreover, if reducing irradiated volumes are safe regarding recurrences, involved-field radiotherapy allowed dose escalation while reducing acute and late oesophageal, cardiac and pulmonary toxicities. Consequently, major clinical trials involving radiotherapy initiated in the las...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research

Related Links:

Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas  [STS], ovarian cancer, breast cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and transitional cell carcinoma [TCC]).
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
Publication date: Available online 25 June 2019Source: Practical Radiation OncologyAuthor(s): Sarah Z. Hazell, Russell K. Hales, William T. Hrinivich, Kristy Ford, Ken Kang-Hsin Wang, Todd R. McNutt, Peijin Han, Lori J. Anderson, Adam C. Ferro, Joseph Moore, Khinh Ranh VoongAbstractPurposeNonhomogeneous dose optimization (NHDO) is exploited in stereotactic body radiation therapy (SBRT) to increase dose delivery to the tumor and allow rapid dose falloff to surrounding normal tissues. We investigate changes in plan quality when NHDO is applied to inverse-planned conventionally fractionated radiation therapy (CF-RT) plans in ...
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 2 August 2019Source: Practical Radiation OncologyAuthor(s): Robert T. Dess, Yilun Sun, Daniel G. Muenz, Peter A. Paximadis, Michael M. Dominello, Inga S. Grills, Larry L. Kestin, Benjamin Movsas, Kathryn J. Masi, Martha M. Matuszak, Jeffrey D. Radawski, Jean M. Moran, Lori J. Pierce, James A. Hayman, Matthew J. Schipper, Shruti Jolly, Michigan Radiation Oncology Quality ConsortiumAbstractPurposeThe heart has been identified as a potential significant organ at risk in patients with locally-advanced non-small cell lung cancer (NSCLC) treated with radiation. Practice patterns and radiation d...
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
This article summarizes the milestones in the development of camrelizumab leading to this first approval for classical Hodgkin lymphoma.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 25 June 2019Source: Practical Radiation OncologyAuthor(s): Sarah Z. Hazell, Russell K. Hales, William T. Hrinivich, Kristy Ford, Ken Kang-Hsin Wang, Todd R. McNutt, Peijin Han, Lori J. Anderson, Adam C. Ferro, Joseph Moore, Khinh Ranh VoongAbstractIntroductionNon-homogeneous dose optimization (NHDO) is exploited in stereotactic body radiotherapy (SBRT) to increase dose delivery to the tumor and allow rapid dose fall-off to surrounding normal tissues. We investigate changes in plan quality when NHDO is applied to conventionally-fractionated inverse-planned radiation (CF-RT) plans, in patie...
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsVMAT is now widely available, and high-quality VMAT plans that incorporate cardiac substructures into the optimization process can provide overall improvements in dose to OARs and, in particular, substantial sparing of critical cardiac structures. IMPT provides some incremental dosimetric improvements beyond cardiac-optimized VMAT, the clinical significance of which remains uncertain.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
This article summarizes the milestones in the development of erdafitinib leading to this first approval for the treatment of urothelial carcinoma.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Abstract Starting from their role exerted on osteoblast and osteoclast differentiation and activity pathways, microRNAs (miRNAs) have been recently identified as regulators of different processes in bone homeostasis. For this purpose, in a recent review, we highlighted, as deregulated miRNAs could be involved in different bone diseases such as osteoporosis. In addition, recent studies supported the concept that osteoporosis-induced bone alterations might offer a receptive site for cancer cells to form bone metastases, However, to date, no data on specific-shared miRNAs between osteoporosis and bone metastases have...
Source: Cellular and Molecular Life Sciences : CMLS - Category: Cytology Authors: Tags: Cell Mol Life Sci Source Type: research
Abstract PURPOSE: To identify published normal tissue complication probability (NTCP) models suitable for patient-specific dose-prescription in locally advanced non-small cell lung cancer (LA-NSCLC) through in-house validation. MATERIAL AND METHODS: From eight previously published candidate NTCP models (≥grade 2 acute esophagitis and radiation pneumonitis; AE2, RP2), patient-specific dose-responses were calculated using model variables and fractionation-corrected doses for 241 LA-NSCLC patients treated with chemo-IMRT to 50-80 Gy@1.8-2.0 Gy between 2004 and 2014 (AE2/RP2 rate: 50%/12%). A model was jud...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
ΜicroRNA‑889 plays a suppressive role in cell proliferation and invasion by directly targeting TAB1 in non‑small cell lung cancer. Mol Med Rep. 2019 May 15;: Authors: Dong Z, Li B, Wang X Abstract MicroRNAs (miRNAs) are frequently reported to be aberrantly expressed in non‑small cell lung cancer (NSCLC) and are closely associated with aggressive tumor phenotypes. Hence, identification of cancer‑related miRNAs in NSCLC may be helpful for improving the cure rate of NSCLC treatments. miR‑889 has been demonstrated to be a novel cancer‑associated miRNA that is aberrantly expressed and plays a...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Endoscopy | Esophagus Cancer | Lung Cancer | Non-Small Cell Lung Cancer | PET Scan | Study | Toxicology